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ABSTRACT
Background: Liver resections (LR) are an obligatory element in the multimodal treatment scheme of colorec-
tal cancer liver metastases (CRCLM). Nowadays still there are debates about the benefit of any aggressive 
surgical approach in noncolorectal cancer liver metastases (NCRCLM) because many authors report desper-
ately high rates of early specific post-resection complications (SPRC) followed by unsatisfactory long term 
results. 
Aim: Comparative analyses between the SPRC after major liver resections (MLR), i.e. ≥ 2 segments of 
CRCLM and NCRCLM for confirming or denying the hypothesis of higher risk in the group of NCRLM. 
Material and methods: A total of 331 MLR of benign and malignant tumors were performed between 
01.01.2007 – 31.12.2014 in the Clinic of Liver, Biliary, Pancreatic and General Surgery, Tokuda Hospital So-
fia. Radical resections received 143 CRCLM patients and 58 NCRCLM patients, both synchronous and meta-
chronous. The design of the study was “a single center” and “retrospective”. The perioperative data of these 
201 patients were analyzed and finally 59 cases of CRCLM (Group 1) and 36 cases of NCRCLM (Group 2) were 
included in the study. All the metastases were metachronous and no significant differences in demography, 
comorbidity, liver function, ASA group, neoadjuvant chemotherapy and surgery specificity were detected 
between the two groups. Cases that were indicated for MLR were those under 65 years of age, with preserved 
liver function, without serious pulmonary and cardiac concomitant diseases, and estimated as ASA group 
≤ III. Data about SPRC were collected and analyzed. Results: The entire early postoperative mortality rate 
was 3.2% (3 fatal outcomes) - 1/59 (1.7%) in group 1 and 2/36 (5.5%) in group 2. The cause of death was liv-
er failure, sepsis and pulmonary embolism. The rate of SPRC was significantly higher in group 2, affecting 
16/36 patients (44.4%) while only 18 out of all the 59 patients (30.5%) in group 1 suffered specific complica-
tions. However only 5.1% and 8.3% of the SPRC necessitated reoperations in group 1 and group 2 respect-
fully. The comparative analysis denied any prognostic value for the early SPRC played by the time of me-
tastases detection, adjuvant chemotherapy, the duration of liver resection procedure and the necessity of 
blood transfusion. Conclusions: Both mortality and specific morbidity after MLR affected patients with ≥3 
comorbid conditions which proved to be the only predictive factor for SPRC. SPRC were more frequent in 
group 2 (NCRCLM) but the great majority of them were solved by conservative measures, less often by inter-
ventional procedure and reoperations were indicated very rarely.
 
Keywords: Colorectal cancer liver metastases (CRCLM); noncolorectal cancer liver metastases 
(NCRCLM); major liver resection (MLR); specific post-resection complications (SPRC)
К. Draganov, А. Petreska, D. Rusenov et al.
Scripta Scientifica Medica, vol. 47, Supplement 1, 2015, pp. 48-54
Copyright © Medical University of Varna   49
BACKGROUND
Ekberg formulated the contraindications 
for colorectal cancer liver metastases (CRCLM) 
resections in 1986: (а) more than 4 lesions; 
(b) extrahepatic involvement, incl. periportal 
lymph node metastases; (c) impossibility of 
resection margin of  at least 1 cm [9]. Since that 
year Ekberg’s criteria have been accepted as the 
“golden standard” in the treatment of CRCLM 
and those of neuroendocrine tumors (NET). 
[1,5,7,10,12,20,21]. There is an “evidence based” 
benefit for those patients concerning long-
term survival rates, decreased tumor toxicity, 
improvement of hepatocyte function, the 
immune competence and increasing the chance 
of chemotherapy response [1,5,7,10,12,19,20]. 
Nowadays still there are debates about the 
benefit of any aggressive surgical approach 
in noncolorectal cancer liver metastases 
(NCRCLM) because many authors report 
desperately high rates of early specific post-
resection complications (SPRC) followed by 
unsatisfactory disease free survival (DFS) and 
over-all survival (OS) [3,6,15,17,19].
AIM OF THE STUDY
Comparative analyses between the 
SPRC after major liver resections (MLR), i.e. 
≥ 2 segments of CRCLM and NCRCLM for 
confirming or denying the hypothesis of higher 
risk in the group of NCRCLM.
MATERIAL AND METHODS  
A total of 331 MLR of benign and 
malignant tumors were performed between 
01.01.2007 – 31.12.2014 in the Clinic of Liver, 
Biliary, Pancreatic and General Surgery, Tokuda 
Hospital Sofia (Table.1). Radical resections 
received 143 CRCLM patients and 58 NCRCLM 
patients, both synchronous and metachronous. 
The design of the study was “a single center” and 
“retrospective”. The perioperative data of these 
201 patients were analyzed and finally 59 cases 
of CRCLM (Group 1) and 36 cases of NCRCLM 
(Group 2) were included in the study. All the 
metastases were metachronous and no significant 
differences in demography, comorbidity, liver 
function ASA group, neoadjuvant chemotherapy 
and surgery specificity were  detected between 
the groups.
The basic steps in the liver resection 
were: (а) intraoperative exploration incl. 
ultrasound; (b) „in-flow control“ – a selective 
clampage was preferred, less often intermittent 
Pringle’s manouvre. Total vascular exclusion 
was performed when suspected blood loss 
was over 1000 ml; (c) gentle and precise 
parenchyma dissection using CUSA knife; (d) 
reliable definitive hemostasis and biliostasis 
on the resection surface; (e) prophylaxis of 
postoperative biliary hypertension by external 
biliary drainage, usually a cystic duct drainage 
installed; (f) adequate drainage of the peritoneal 
cavity. 
The definitions of the International Study 
Group of Liver Surgery (ISGLS) about the liver 
resection volume and the local and general 
SPRC were used. [16]. All the data were analyzed 
statistically with the help of variation and 
alternative analyses, t-value and Fisher’s exact 
test. Statistically significant differences were 
considered for P<0.05.
RESULTS
The demographic data were statistically 
similar (Table. 2). Only one female patient 
from Group 2 was 72 years of age but the lack 
of significant comorbidity, the normal range of 
laboratory tests, the good performance status 
and the ASA II made us undertake a radical 
surgical procedure. All the rest of the patients 
were < 65 years of age. 
Comorbodity was “remarkable” in both 
groups affecting 2/3 of all cases with a slight 
but not statistically significant prevalence in the 
NCRCLM group – 72.2% vs 66.1% (Table.3). 
The detailed analysis of comorbidity as 
„type” and „severity” proved that all the patients 
but one had ≤ 3 cormobid conditions of the 
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Basic Diagnosis 
No of 
cases % Male female
1. Colorectal Liver Metastases 143 43,20% 91 52 
2. Noncolorectal Liver Metastases 
2.1. Gastric cancer liver metastases – synchronous and metachronous 
2.2. Pancreatic cancer liver metastases – synchronous and metachronous 
2.3. Other malignant tumor metastases – breast cancer,  
GIST, common bile duct, gall bladder, ovarial cancer  

























3. Primary liver cancer  (hepatocellular cancer - 29; 
cholangicarcinoma - 13) 42 12,69% 23 19 
4. Benign liver tumors 33 9,97% 11 22 
5. Hydatid liver disease   36 10,88% 22 14 
6. Liver abscesses 12 3,63% 6 6 
7. Liver cysts 7 2,11% 2 5 
Total 331 100,00% 184 147
Criterion Group 1 (CRLM) Group 2 (NCRLM) „р“ 
Median age 56.22 +/- 6.876 год. 54.31 +/- 5.326 год. р>0.05 
Sex (male/female) 29(49.2%) / 30 (50.8%) 17 (47.2%) / 19 (52.8%) р>0.05 
Group 
Group 1 CRCLM Group 2 NCRLM 
Table. 1. Indications for radical MLR and multi-organ resections in Tokuda Hospital (2007-2014)
Table. 2. Sex and age distribution of patients from group 1 and group 2
Table. 3. Distribution of patients from group 1 and group 2 according to comorbidity (CoM)
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following (table.4):  (а) cardio-vascular; (b) 
pulmonary; (c) anemia; (d) diabetes; (e) others. 
The lab tests showed mild but not severe 
deviations in RBC and Hb, blood sugar, 
albumin, ASAT, ALAT, bilirubin, coagulation. 
Preoperative conservative measures (blood and 
plasma transfusions, hepatocyte protectors, 
vitK, Insulin, others) aimed corrections. We 
have never undertaken MLR in cases of serious 
liver function disturbances – total bilirubin > 21 
µmol/l, ASAT and ALAT > 80 UI/l, INR > 1,35 
and АРТТ > 35 sec. All patients from the study 
were ASA ≤ 3. 
The median period of detection of 
metachronous NCRCLM was 11.7 months (6-
37 months) after previous curable pancreatic 
resections, 11.0 months (7-18 months) after 
gastrectomy and 28.1 months (24-39 months) 
after surgery on other types of cancer. Adjuvant 
chemotherapy was received by 53 CRCLM 
patients (89.8%) and 30 NCRCLM patients 
(83.3%). 
Anatomical LR accounted for 55.8% in 
the whole series - 33/59 (55.9%) in group 1 and 
20/36 (55.6%) in group 2. The median surgical 
procedure duration was 4.02 hours (3-7 hours) 
in group 1 and 4.58 hours (3-7 hours) in group 2. 
Blood transfusion needed 25 of the 59 CRCLM 
patients (42.8%) and 16 of the 36 NCRCLM 
patients (44.4%). The mean transfused quantity 
was 0.81 RBC packs (concentrate unit) per 
patient. 
The entire early postoperative mortality 
rate was 3.2% (3 fatal outcomes) - 1/59 (1.7%) in 
number of comorbid conditions Group 1 (CRCLM) Group 2 (NCRCLM) 
0 (no comorbidity) 20 (33,9%) 10 (27,8%) 
1 comorbid condition 16 (27,1%) 12 (33,3%) 
2 comorbid conditions 12 (20,3%) 11 (30,6%) 
3 comorbid conditions 9 (15,3%) 3 (8.4%) 
4 comorbid conditions 2 (3,4%) 0 (0%) 
5 comorbid conditions 0 (0%) 0 (0%) 
Total 59 (100.0%) 36 (100.0%) 
Complications – code* Group 1 (CRCLM) Group 2 (NCRCLM) 
Code 0  41 (69,5%) 20 (55,6%) 
Code 1  10 (16,9%) 10 (27,8%) 
Code 2 5 (8,5%) 3 (8,3%) 
Code 3  3 (5,1%) 3 (8,3%) 
Total 59 (100.0%) 36 (100.0%) 
Table 4. Distribution of patients from group 1 and group 2 according to the number of comorbid conditions 
Table. 5. Early specific postresection complications (SPRC) after MLR of CRCLM and NCRCLM 
* Code for the „type of complication“:  0 – no SPRC registered;  1 – SPRC, treated conservatively;  2 – SPCR, treated by an 
interventional procedure (percutaneous drainage under US guide; pig-tail catheter; drainage of a pleural effusion); 3 – 
SPRC necessitating reoperation
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group 1 and 2/36 (5.5%) in group 2. The cause 
of death was liver failure, sepsis and pulmonary 
embolism.
The rate of SPRC was significantly higher 
in group 2, affecting 16/36 patients (44.4%). Only 
18 out of all the 59 patients (30.5%) in group 
1 suffered specific complications. However 
only 5.1% and 8.3% of the SPRC necessitated 
reoperations in group 1 and group 2 respectfully 
(table.5). 
Correlation analysis showed that none 
of the listed below proved to be a risk factor 
for postoperative morbidity and mortality, i.e. 
age, time of detection of metachronous lesions, 
duration of surgery and the blood loss quantity. 
The presence of more than 3 comorbid conditions 
was the only risk factor for higher morbidity and 
mortality rates. 
DISCUSSION
During the last three decades liver 
resection surgery in oncology is more and more 
aggressive especially in the so called „marginal 
curable cases“. Results permanently get better 
and better due to improved surgical technique, 
methods of anesthesia, hepatocyte protection 
and intensive postoperative care. Morbidity in 
experienced centers is less than 25% (in some 
series even 5-6%), while mortality rate trends 
0% [10,11,13,14]. To our opinion an explanation 
is necessary about those data. Probably some 
of those data are speculative because not all 
the authors define the “liver resection volume” 
and “major liver resection” (MLR) in their 
reports. Thus one and the same study includes 
MLR together with wedge resections, simple 
tumorectomies, enucleations, even biopsies. 
MLR such as right or left hemihepatectomies 
and  trisectionectomies show a morbidity rate 
between 11% and 34% [8,18]. 
The benefit of multivisceral resections of 
synchronous NCRCLM including gastrectomy 
or pancreatic resection plus metastasectomy or 
MLR is still a matter of debate according to some 
authors and a certain issue of according to others 
[3,6,15,17,19]. The attitude towards hepatic 
metastasectomy or MLR of metachronous 
metastases of gastric, pancreatic, gynecological 
and urological cancer, sarcomas, melanomas, 
others is almost the same [3,6,17,19].
MLR are contraindicated in the great 
majority of patients because of multiplicity and/
or bilobar involvement (H2, H3) as well as a 
peritoneal dissemination exists in many of the 
gastric or pancreatic carcinomas [17]. Studies 
show a desperately high recurrence incidence of 
resected metachronous NCRCLM which varies 
from 63.6% to 91.0% [17].  
It was on the “107er Congrés Français de 
Chirurgie”, Paris, Arnette, 2005 when R.Adam 
and L.Chiche presented a report titled „Chirurgie 
des métastases hépatiques de cancers non 
colo-rectaux non endocrine“ [4]. The authors 
emphasized on the fact that they had found less 
than 80 articles in English treating the problems 
of the surgical treatment of NCRCLM. R.Adam 
and L.Chiche analyzed the reported data as 
well as their own institutional experience and 
concluded about the “incorrectness and laps” 
of many of the studies, i.e. including less than 
20 cases, different primary cancer site, different 
histology, biology and tumor aggressiveness. 
In 2006 the same authors published a 
retrospective analysis of 1492 patients with 
NCRCLM who had received surgery in 41 French 
hospitals [3]. The approach was differentiated 
according to the type and primary tumor site, 
the time of detection and some demographic 
data. However, the study of R.Adam et al. is 
more or less epidemiological and aimed at 
the cancer population in general than at the 
individual patient. The “risk model” proposed 
by the authors helps the judgment of an eventual 
benefit for the patient’s long term survival which 
advocates an aggressive surgical approach. Our 
study was focused on the early postoperative 
results (morbidity and mortality rates) aiming 
an “individual approach based algorithm” for 
cases of NCRCLM.  
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CONCLUSIONS
Aggressive MLR of metachronous and 
synchronous CRCLM and NCRCLM have 
oncologic justification in selected patients. 
As “selected patients” we define those who 
are under 65 years of age, with preserved liver 
function, without serious pulmonary and 
cardiac concomitant diseases, and estimated 
as ASA group ≤ III. The time of metastases 
detection, adjuvant chemotherapy, duration 
of liver resection procedure and the necessity 
of blood transfusion didn’t play statistically 
significant predictive value. 
Both mortality and specific morbidity 
affected patients with ≥3 comorbid conditions 
which proved to be the only predictive factor 
for SPRC. SPRC were more frequent in the 
NCRCLM group 2 but the great majority of them 
were solved by conservative measures, less often 
by interventional procedure and reoperations 
were indicated very rarely. 
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